173 related articles for article (PubMed ID: 1678695)
21. Aldosterone response to metoclopramide in patients with prolactinoma: effect of short-term bromocriptine treatment.
Zacharieva S; Stoeva I; Andreeva M; Kalinov K; Matrozov P; Andonova K
Methods Find Exp Clin Pharmacol; 1996 Nov; 18(9):593-7. PubMed ID: 9010834
[TBL] [Abstract][Full Text] [Related]
22. Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up.
Hildebrandt G; Bauer T; Stracke H; Fassbender WJ; Mueller HW; Agnoli AL; Federlin K; Roosen K
Zentralbl Neurochir; 1992; 53(3):123-34. PubMed ID: 1414079
[TBL] [Abstract][Full Text] [Related]
23. [The treatment of prolactinoma].
Serri O; Somma M; Beauregard H; Rasio E; Comtois R; Aris-Jilwan N; Boucher A; Hardy J
Union Med Can; 1993; 122(6):496-9. PubMed ID: 7905686
[TBL] [Abstract][Full Text] [Related]
24. Light microscopical morphometry of prolactin secreting adenomas under treatment with dopamine agonists.
Hamester U; Saeger W; Lüdecke DK
Histol Histopathol; 1987 Apr; 2(2):135-42. PubMed ID: 2980713
[TBL] [Abstract][Full Text] [Related]
25. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
[TBL] [Abstract][Full Text] [Related]
26. CV205-502, a new non-ergot dopamine agonist, reduces prolactinoma size in man.
Barnett PS; Dawson JM; Butler J; Coskeran PB; Maccabe JJ; McGregor AM
Clin Endocrinol (Oxf); 1990 Aug; 33(2):307-16. PubMed ID: 1977537
[TBL] [Abstract][Full Text] [Related]
27. Prolactinomas and resistance to dopamine agonists.
Brue T; Pellegrini I; Priou A; Morange I; Jaquet P
Horm Res; 1992; 38(1-2):84-9. PubMed ID: 1306523
[TBL] [Abstract][Full Text] [Related]
28. Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma.
Bodmer CW; Atkin SL; Savage MW; Masson EA; White MC
Clin Endocrinol (Oxf); 1995 Jul; 43(1):49-53. PubMed ID: 7641411
[TBL] [Abstract][Full Text] [Related]
29. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
Colao A; Merola B; Sarnacchiaro F; Di Sarno A; Landi ML; Marzullo P; Cerbone G; Ferone D; Lombardi G
Horm Res; 1995; 44(5):222-8. PubMed ID: 8582715
[TBL] [Abstract][Full Text] [Related]
30. Potential for long-term remission of microprolactinoma after withdrawal of dopamine-agonist therapy.
Bronstein MD
Nat Clin Pract Endocrinol Metab; 2006 Mar; 2(3):130-1. PubMed ID: 16932269
[No Abstract] [Full Text] [Related]
31. Resistance to bromocriptine in prolactinomas.
Pellegrini I; Rasolonjanahary R; Gunz G; Bertrand P; Delivet S; Jedynak CP; Kordon C; Peillon F; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
[TBL] [Abstract][Full Text] [Related]
32. [Hyperprolactinemia and prolactinomas. Results of surgical and drug therapy].
Brabant G; Brennecke I; Herrmann H; Friedrich H; Wagner TO; von zur Mühlen A; Hesch RD
Dtsch Med Wochenschr; 1985 Oct; 110(41):1564-7. PubMed ID: 4042883
[TBL] [Abstract][Full Text] [Related]
33. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
34. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine.
Merola B; Sarnacchiaro F; Colao A; Di Somma C; Di Sarno A; Ferone D; Selleri A; Landi ML; Schettini G; Nappi C
Gynecol Endocrinol; 1994 Sep; 8(3):175-81. PubMed ID: 7847102
[TBL] [Abstract][Full Text] [Related]
35. Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas.
Serri O; Beauregard H; Lesage J; Pedneault L; Comtois R; Jilwan N; Somma M; Vachon L; Brownell J
J Clin Endocrinol Metab; 1990 Sep; 71(3):682-7. PubMed ID: 2394774
[TBL] [Abstract][Full Text] [Related]
36. Dopamine agonists and pituitary tumor shrinkage.
Bevan JS; Webster J; Burke CW; Scanlon MF
Endocr Rev; 1992 May; 13(2):220-40. PubMed ID: 1352243
[TBL] [Abstract][Full Text] [Related]
37. Disappearance of a pituitary tumor after 15 months of treatment with CV 205-502, a new dopamine agonist.
Fassbender WJ; Stracke H; Bachmann G; Rau W; Federlin K
Clin Investig; 1992 May; 70(5):444-6. PubMed ID: 1350936
[TBL] [Abstract][Full Text] [Related]
38. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy.
Morange I; Barlier A; Pellegrini I; Brue T; Enjalbert A; Jaquet P
Eur J Endocrinol; 1996 Oct; 135(4):413-20. PubMed ID: 8921822
[TBL] [Abstract][Full Text] [Related]
39. [Prolactinoma and pregnancy].
Trifonov I
Akush Ginekol (Sofiia); 2004; 43 Suppl 2():16-22. PubMed ID: 15518268
[No Abstract] [Full Text] [Related]
40. Treatment of prolactinoma patients with the new non-ergot dopamine agonist roxindol: first results.
Jaspers C; Benker G; Reinwein D
Clin Investig; 1994 Jun; 72(6):451-6. PubMed ID: 7950157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
